GlaxoSmithKline, alongside Nasdaq-listed partner Innoviva, announced the publication of the landmark IMPACT study - one of the biggest ever conducted in patients with chronic obstructive pulmonary disease with a history of exacerbation - in the New England Journal of Medicine on Thursday. The FTSE 100 pharmaceutical giant said that n the study, 'Trelegy Ellipta' (fluticasone furoate/umeclidinium/vilanterol) achieved superiority to members of two different classes of dual combination therapy, ...Den vollständigen Artikel lesen ...